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A B S T R A C T
Clinical isolates of methicillin-resistant Staphylococcus aureus (n ¼ 1070) collected from 63 French general
hospitals during June 2000 (n ¼ 1070) were screened initially for reduced susceptibility to glycopeptides
(GISA) on brain–heart infusion agar containing teicoplanin 6 mg ⁄L. Glycopeptide MICs were
determined for the 145 isolates that grew on the screening plates. Of the 1070 isolates, 1.4% were
GISA on Mueller–Hinton agar, and 2.9% by Etest with a high inoculum, while 0.7% and 2.9%
were GISA by vancomycin and teicoplanin population analysis profiles, respectively. Most isolates were
resistant to gentamicin and rifampicin or fosfomycin or fusidic acid, as determined by disk diffusion.
Pulsed-field gel electrophoresis of the 31 GISA isolates identified four clones, with dissemination of one
predominant clone. In these French hospitals there was a low incidence of GISA and hetero-GISA.
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I N T R O D U C T I O N
Methicillin-resistant Staphylococcus aureus (MRSA)
is a major cause of hospital-acquired infection
throughout the world. The proportion of MRSA
among nosocomial S. aureus causing bacteraemia
in French hospitals is 47% [1]. The main antibi-
otics used to treat these infections are the glyco-
peptides, but following the emergence of
vancomycin resistance in enterococci and coagu-
lase-negative staphylococci, MRSA strains with
reduced susceptibility to glycopeptides (GISA)
have been reported in Japan, France, Spain,
Sweden, the UK, Hong Kong and the USA [2–7].
Various methods are used to detect GISA strains
[2,8]. The aim of this study was to determine the
proportion of MRSA with reduced susceptibility
to glycopeptides in 63 French general hospitals.
M A T E R I A L S A N D M E T H O D S
In total, 1070 MRSA isolates from infection and colonisation
samples were collected during June 2000 from 63 French
general hospitals. The mean number of strains ⁄hospital was
17, and the numbers ranged from three to 61; 106 were
duplicate isolates. The isolates were screened on brain–heart
infusion agar (BHIA) (AES Laboratoire, Combourg, France)
containing teicoplanin 6 mg ⁄L, with a 10-lL inoculum of a 0.5
McFarland bacterial suspension as described previously [2].
This study was designed before the French Society for
Microbiology chose its method for screening GISA. The
reference strains Mu3 (hGISA), Mu50 (GISA) and ATCC
25923 (a susceptible strain) were used as controls. Glycopep-
tide MICs were determined for isolates that grew on the
screening plates by antibiotic dilution in Mueller–Hinton (MH)
agar (AES Laboratoire) and inoculation with a 0.5 McFarland
suspension (104 CFU ⁄ spot), and similarly on BHIA after
incubation for 24 h. Vancomycin and teicoplanin Etests were
performed with a 2 · McFarland suspension in BHI broth
(200 lL) swabbed on to BHIA and incubated for 48 h.
An isolate was defined as GISA if the vancomycin or
teicoplanin MIC on MH agar was >4 mg ⁄L (http://
www.sfm.asso.fr/) and by Etest on BHIA if the vancomycin
and teicoplanin MICs were ‡ 8 mg ⁄L, or if the teicoplanin
MICs were ‡ 12 mg ⁄L [8]. Susceptibility to gentamicin, rif-
ampicin, fosfomycin and fusidic acid was determined by disk
diffusion (Bio-Rad, Marne la Coquette, France) on MH agar.
Population analysis profiles (PAPs) were determined with
inocula (100 lL) of 103 CFU and 106 CFU plated on BHIA
containing serial dilutions of vancomycin and teicoplanin from
0.12 to 128 mg ⁄L. Colonies were counted after 48 h. The PAP
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was compared to that of Mu3, and an area under the curve
ratio of ‡ 0.9, in comparison with Mu3, was used to define a
GISA strain [6].
Pulsed-field gel electrophoresis (PFGE) was performed on
GISA isolates, following the methodology proposed by Chung
et al. [9]. Isolates that differed by three or more bands were
considered divergent. Profiles differing by only one or two
bands were considered to be minor variants of a common
epidemic strain.
R E S U L T S
The vancomycin MICs on MH agar for Mu3, Mu50
and ATCC 25923 were 2, 8 and 1 mg ⁄L, respect-
ively, and the teicoplanin MICs on MH agar were
16, 8 and 1 mg ⁄L, respectively. The Etest MICs
were 4, 8 and 2 mg ⁄L for vancomycin, and 16, 12
and 2 mg ⁄L for teicoplanin, respectively.
Of the 1070 strains in the study, 145 (13.6%)
grew on the screening plates, but only 63 (5.9%)
strains had a teicoplanin MIC ‡ 6 mg ⁄L on BHIA.
Fifteen (1.4%) strains from ten hospitals had
teicoplanin MICs > 4 mg ⁄L on MH agar and were
thus considered to be GISA according to the
French definition. No strain had a vancomycin
MIC > 4 mg ⁄L on MH agar. Thirty-one (2.9%)
strains from 18 hospitals were identified as GISA
according to the Etest method (Table 1). Of these,
13 had vancomycin and teicoplanin MICs
‡ 8 mg ⁄L; the remaining 18 had teicoplanin MICs
‡ 12 mg ⁄L. According to vancomycin PAP and
Etest criteria, seven (0.65%) strains were consid-
ered to be GISA, while according to teicoplanin
PAP, 31 (2.9%) strains were classified as GISA.
Table 2 presents the results of testing suscepti-
bility to teicoplanin by different methods.
Twenty-one isolates were susceptible according
to all three tests. Eight isolates were GISA accord-
ing to all three methods. Twelve were GISA
according to the PAP and Etest results; the
teicoplanin MIC on MH agar for these strains
ranged between 3 and 4 mg ⁄L. The other strains
(n ¼ 22) had a discrepancy between the teicopl-
anin PAP results and the Etest definition for
GISA: 11 were positive by Etest and negative by
teicoplanin PAP; however, the area under the
curve ratios (0.85–0.88) were very close to the cut-
off value. In contrast, 11 were teicoplanin PAP-
positive and Etest-negative, with Etest results
(vancomycin, 6 mg ⁄L; teicoplanin, 8 mg ⁄L) very
close to the cut-off value. One of the strains
belonged to a duplicate pair, but this pair consis-
ted of one GISA isolate (Etest MIC of vancomy-
cin ⁄ teicoplanin ¼ 4 ⁄ 12 mg ⁄L) and one non-GISA
isolate (Etest MIC of vancomycin ⁄ teicopla-
nin ¼ 6 ⁄ 8 mg ⁄L). It was noted that 19 strains
had teicoplanin MICs of 4 mg ⁄L (i.e., defined as
susceptible), but had a teicoplanin MIC that was
four-fold higher than that of the susceptible
control strain ATCC 25923.
Among the 31 GISA isolates (detected on MH
agar or by Etest), three were susceptible to
gentamicin, 24 were resistant to gentamicin and
another drug (rifampicin, fosfomycin or fusidic
acid), and four were resistant to gentamicin, but
susceptible to rifampicin, fosfomycin and fusidic
acid. Among the 63 isolates with teicoplanin MICs
‡ 6 mg ⁄L on BHIA, 24 were resistant to gentam-
icin and another antibiotic (rifampicin, fosfomy-
cin or fusidic acid), but were not defined as GISA.
However, these isolates were less susceptible to
glycopeptides than the susceptible control strain.
PFGE performed on the GISA isolates detected
four different genotypes (Fig. 1). One pattern (A)
was predominant and was shared by 25 strains,
while pattern B was shared by four strains, and
Table 1. Vancomycin and teicoplanin MICs determined
by different methods for the 63 MRSA isolates that had
initial teicoplanin MICs ‡ 6 mg ⁄L on BHIA
MIC
(mg ⁄L)
Number of isolates
Vancomycin
in MH agar
Teicoplanin
in MH agar
Vancomycin
Etest on BHIA
Teicoplanin
Etest on BHIA
24 2
16 a 9a
12 2 20b
8 b 5b 5b 18
6 4 10 6
5 6
4 19 36a 5
3 1 23 8 3
2 49a 6 2c c
1 13c c
aMIC for Mu3 (hGISA).
bMIC for Mu50 (GISA).
cMIC for ATCC 25923 (susceptible control strain).
Table 2. GISA definition results for 63 MRSA isolates with
initial teicoplanin MICs ‡ 6 mg ⁄L on BHIA
Number of strains
GISA definition method
Teicoplanin PAP
on MH agar Teicoplanin MIC
Etest on
BHIA
7 – – +
4 – + +
8 + – –
3 + + –
8 + + +
12 + – +
21 – – –
PAP, population analysis profile.
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two strains had unique patterns (C and D).
Pattern A was present in isolates from 14 hospi-
tals, and five hospitals yielded at least two
isolates. Pattern B was found in three hospitals,
of which one yielded two isolates. Four different
scenarios of GISA dissemination were observed:
first, epidemic transmission of GISA isolates with
the same PFGE pattern and the same antimicro-
bial susceptibilities; second, epidemic transmis-
sion of GISA with the same PFGE pattern, but
different antimicrobial susceptibilities; third, in
one hospital, the presence of two GISA isolates
with different PFGE patterns and different anti-
microbial susceptibilities; and fourth, in another
hospital, the presence of two GISA isolates with
different PFGE patterns, but the same antimicro-
bial susceptibility pattern.
D I S C U S S I O N
GISA isolates have been recovered in Europe, the
USA, Japan and Korea. French hetero-GISA
(hGISA) isolates have been shown to be clonally
diverse, although clonal epidemic isolates have
also been described [2–7,10,11]. However, GISA
isolates are found rarely in France, and hGISA
isolates represent the most frequent isolates; the
latter have been present since at least 1993 [12].
hGISA may mutate to GISA, but not all workers
have been able to demonstrate this finding [13].
Resistance to methicillin is a common trait of most
GISA strains described so far, but Reverdy et al.
reported a methicillin-susceptible hGISA strain
[5]. The same authors reported an incidence of
0.6% for GISA and hGISA from 640 S. aureus
isolates. The present study showed a range of 1.4–
2.9%, depending on the method used. The Etest
and teicoplanin PAP results were in general
agreement, although one strain gave borderline
results with the two methods. Such strains have
reduced susceptibility to glycopeptides at the
limit of GISA definition, but they differ from
susceptible strains which have MICs close to
those of strain ATCC 25923. The Etest macro-
method detected these strains readily, and these
strains should be evaluated further as potential
sources of treatment failure [14]. The French
guidelines (http://www.sfm.asso.fr/) identified
a lower percentage of GISA than the Etest method
on BHIA (1.4% vs. 2.9%) [8], although, whatever
method was used, the percentage of hGISA was
low in French hospitals. Indeed, according to the
National Committee for Clinical Laboratory
Standards definition (http://www.cdc.gov), no
GISA strains were present in this survey. The
association of lower susceptibility to glycopep-
tides with resistance to gentamicin and other
antimicrobial agents, such as rifampicin, fosfo-
mycin and fusidic acid, is a cause for concern, as it
has been shown that stable progeny homogen-
eously resistant to vancomycin can be selected
rapidly from hGISA [15]. Treatment of infections
caused by such strains would be very difficult.
Even if GISA isolates are scarce and therapeutic
failures are rare, vancomycin and teicoplanin
MICs must be determined for cases of serious
infection in patients with underlying disease (e.g.,
diabetes mellitus, chronic and acute renal failure,
cancer, leukaemia) in order to detect such strains
and monitor antibiotic dosage, especially in cases
of wound infection, endocarditis, meningitis,
osteomyelitis or bacteraemia. In this study, PFGE
analysis, performed on 31 GISA isolates, defined
four clones, one being predominant and present
in 14 hospitals. Similarly, Lecaillon et al. reported
the endemic spread of hGISA, with three clones
present in the same hospital [16]. When a GISA
strain is detected, implementation of standard
infection control guidelines for patients with
MRSA should help to prevent the spread of these
strains.
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